Correction to: Nature Communications https://doi.org/10.1038/s41467-024-51057-7, published online 07 August 2024
In the Author Correction, the wrong article title and author list were inadvertently captured.
The title was incorrectly given as ‘Author Correction: dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe’ but should have been ‘Author Correction: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial’. The incorrect author list was given and has been updated to match the original article. The original Author Correction article has been corrected.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gong, H., Tian, S., Ding, H. et al. Publisher Correction: Author Correction: Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial. Nat Commun 15, 8258 (2024). https://doi.org/10.1038/s41467-024-52656-0
Published:
DOI: https://doi.org/10.1038/s41467-024-52656-0
